Provided are a polypeptide antigen derived from the S protein of SARS-CoV-2, a polypeptide vaccine containing the same, and applications thereof. The amino acid sequence of the polypeptide antigen provided by the present disclosure is as shown in any one of SEQ ID NOs: 1-116.
C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
2.
DIAPHRAGMATIC SURFACE SMOOTHNESS CALCULATION METHOD BASED ON LIPSCHITZ EXPONENT
The present application provides a diaphragmatic surface smoothness calculation method based on a Lipschitz exponent. The method comprises: extracting a lung contour; extracting lung feature points; extracting a diaphragmatic surface contour line; calculating Lipschitz exponents of a diaphragmatic surface; and taking the mean value of the calculated Lipschitz exponents of the feature points as the diaphragmatic surface smoothness. According to the present application, the Lipschitz exponents are used for quantitatively measuring the diaphragmatic surface smoothness, so that the deviation caused by subjective experience of a doctor is overcome; and the larger the Lipschitz exponent is, the less smooth the diaphragmatic surface is, and the smaller the Lipschitz exponent is, the smoother the diaphragmatic surface is, thereby providing an objective reference for a clinician to determine diaphragmatic surface smoothness.
Provided are an autophagosome, an extraction method therefor and the use thereof. Provided is a method for extracting a new extracellular vesicle that inhibits ferroptosis, i.e., an autophagosome, which has the advantages of being easy to acquire and not requiring special stimulation for maternal cells, is suitable for large-scale extraction, and has a powerful clinical potential application value. Also provided is an autophagosome obtained using the above extraction method. In examples, a fibroblast ferroptosis model is constructed using high concentration glucose, and the autophagosome is used for verification. It is confirmed that the autophagosome can reduce the sensitivity of cells to ferroptosis and enable the cells to escape from adverse factors inducing ferroptosis.
Provided are a hypoxia-induced human umbilical cord mesenchymal stem cell exosome, a preparation method therefor and a use thereof. Provided is an exosome having high expression of miR-17-5p. The exosome is secreted by hypoxia-induced human umbilical cord mesenchymal stem cells. High expression of miR-17-5p can be realized by preparing a human umbilical cord mesenchymal stem cell exosome by using a hypoxic condition. The expression quantity of miR-17-5p in the exosome having high expression of miR-17-5p is remarkably higher than the expression quantity of miR-17-5p in a normoxia-induced human umbilical cord mesenchymal stem cell exosome. The exosome of the present invention is used for a diabetic wound, has a treatment effect on the diabetic wound remarkably superior to that of an exosome prepared under a normoxic condition, has a higher healing speed, and has greater application potential in the aspects of stimulating skin appendages regeneration and improving the healing quality.
An engineered exosome for promoting the healing of diabetic wounds, and a preparation method therefor and the use thereof. Provided is a method for preparing an engineered exosome for promoting the healing of diabetic wounds. The method comprises the following steps: infecting mesenchymal stem cells with miR-17-5p overexpression lentivirus, and screening same to obtain a stably transfected cell line; subjecting the stably transfected cell line to amplification culture, and extracting an exosome, so as to obtain the engineered exosome for promoting the healing of diabetic wounds. The exosome obtained by the preparation method can significantly protect diabetic wounds and promote the healing of the wounds more quickly.
The present disclosure belongs to the technical field of amniotic membrane, and in particular, relates to a porous biological amniotic membrane puncture device and a preparation method. The device includes a sliding table, a light-shielding frame, a base I, and a base II. The sliding table is provided with a first sliding groove; the light-shielding frame is slidably connected to the first sliding groove; a three-axis movable platform is disposed on the base I; the three-axis movable platform is fixedly connected to a laser puncture device; an upper end of the base II is fixedly connected to a fixed board surface; a middle portion of the fixed board surface is provided with an embedded groove; and an amniotic membrane sample is placed in the embedded groove.
Disclosed are a composition and a use thereof. The composition comprises a liposome, wherein the liposome is composed of a phospholipid and a sterol; a chitosan and/or chitosan derivative coating the liposome; and a polypeptide antigen, wherein the polypeptide antigen is encapsulated in the liposome.
Provided are a class of ultrahigh-affinity small proteins targeting PD-L1 and the use. A class of binding proteins can target PD-L1 and has an ultrahigh affinity. The proteins can competitively bind to wild-type PD-1. The affinity to PD-L1 is much higher than the affinity of the wild-type PD-1 to PD-L1. A fusion protein contains the ultrahigh-affinity protein targeting PD-L1 is also provided.
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
C12N 15/62 - DNA sequences coding for fusion proteins
9.
FRACTURE REPAIR DEVICE REALIZING TRANSITION FROM MECHANICAL FIXATION (ASSOCIATION OF OSTEOSYNTHESIS, AO) TO BIOLOGICAL FIXATION (BIOLOGICAL OSTEOSYNTHESIS, BO)
BEIJING CHUNLIZHENGDA MEDICAL INSTRUMENTS CO., LTD (China)
Inventor
Peng, Jiang
Wang, Zhenguo
Meng, Haoye
Lu, Qiang
Pan, Chao
Yue, Shujun
Wang, Aiyuan
Zhou, Hao
Xu, Wenjing
Liu, Wei
Zhang, Xingyan
Shi, Chunbao
Cheng, Xi
Abstract
The present disclosure discloses a fracture repair device realizing transition from mechanical fixation (association of osteosynthesis, AO) to biological fixation (biological osteosynthesis, BO), including: a bone repair instrument, wherein auxiliary components are arranged at positions, close to a repaired bone surface, of the bone repair instrument, and each auxiliary component is made of a degradable metal material or a composite material thereof or a degradable polymeric material. The device of the present disclosure only has the advantages of AO rigid mechanical fixation, but also can effectively improve the defects of bone disconnection, fixed segment osteoporosis, re-fracture after defixation, etc., frequently occurring under AO rigid mechanical fixation, realizing transition from mechanical fixation (association of osteosynthesis, AO) to biological fixation (biological osteosynthesis, BO) during bone fixation or repair.
The present disclosure provides methods, reagents, compositions, systems and kits for high-throughput drug screening by using barcode molecules. In some embodiments, the method uses one step RT-PCR to simplify the experimental procedure and avoid RNA contamination in the experimental process.
The present disclosure provides a photocurable hydrogel loaded with VH298-modified exosome and a method of preparation and use thereof, belonging to the technical field of medical materials. In the present disclosure, an engineered exosome (VH-EVs) is prepared by combining an exosome with VH298, a hypoxia-inducible factor 1 alpha (HIF-1α) stabilizer; and a solid auxiliary material is loaded by a GelMA hydrogel. The material is not only conducive to sustained release of the engineered exosome, but improves angiogenesis and accelerate wound healing, showing a relatively high value for use.
A repair device for a proximal humerus fracture, comprising a stable structure in which a humerus medullary cavity support part (1), a first insertion body (6), a fitting part and a second insertion body (14) are connected to the humerus, the first insertion body (6) and the second insertion body (14) being combined, the first insertion body (6) being connected to the humeral head (3), and the second insertion body (14) being clamped to the fitting part. The repair device has high strength, so that when the repair device is implanted into the body of a patient, a fractured part of the patient is almost capable of full-range early mobilization right after the completion of the surgery on the patient, thus facilitating the recovery of the joint at the repaired fractured part. In addition, a threaded end (7) of the first insertion body (6) is fixedly connected to the humeral head (3) so as to fixedly connect the repair device and the humeral head (3), and the second insertion body (14) is connected to the first insertion body (6) in an adjustable mode, so that the position of the humeral head (3) fixedly connected to the first insertion body (6) can be adjusted by means of the second insertion body (14), and thus the humeral head (3) at a fracture position can be accurately positioned in surgery, which facilitates subsequent recovery.
The present invention provides an ultra-high affinity small protein targeting a Spike protein (S protein) of a novel coronavirus (COVID-19) mutant strain Delta and a use thereof. Specifically, the present invention provides a binding protein targeting a Spike protein of a COVID-19 mutant strain Delta and having ultra-high affinity. The protein of the present invention can bind to an S protein RBD region, and can block the binding of COVID-19 and an ACE2 receptor, thereby blocking COVID-19 from invading a host cell. The present invention further provides an ultra-high affinity fusion protein targeting the S protein of the COVID-19 mutant strain Delta, and the protein shows good neutralization protection activity for the COVID-19 mutant strain Delta, also shows good neutralization protection activity for wild-type COVID-19 and main mutant strains Alpha, Beta and Gamma thereof, and shows broad-spectrum blocking protection activity for COVID-19.
Provided are a SARS-CoV-2 S protein polypeptide antigen and an application thereof. The amino acid sequence of the SARS-CoV-2 S protein polypeptide antigen provided by the present invention is as shown in any one of SEQ ID NOs: 1-116.
A method for predicting the morphological changes of liver tumor after ablation based on deep learning includes: obtaining a medical image of liver tumor before ablation and a medical image of liver tumor after ablation; preprocessing the medical image of liver tumor before ablation and the medical image of liver tumor after ablation; obtaining a preoperative liver region map, postoperative liver region map, and postoperative liver tumor residual image map; obtaining a transformation matrix by a Coherent Point Drift (CPD) algorithm and obtaining a registration result map according to the transformation matrix; training the network by a random gradient descent method to obtain a liver tumor prediction model; using the liver tumor prediction model to predict the morphological changes of liver tumor after ablation. The method provides the basis for quantitatively evaluating whether the ablation area completely covers the tumor and facilitates the postoperative treatment plan for the patient.
Provided are a class of ultrahigh-affinity small proteins targeting PD-L1 and the use. Specifically, provided is a class of binding proteins targeting PD-L1 and having an ultrahigh affinity, wherein the proteins can competitively bind to wild-type PD-1, and the affinity thereof to PD-L1 is much higher than the affinity of the wild-type PD-1 to PD-L1. Further provided is a fusion protein comprising the ultrahigh-affinity protein targeting PD-L1.
The present disclosure provides methods, reagents, compositions, systems and kits for high-throughput drug screening by using barcode molecules. In some embodiments, the method uses one step RT-PCR to simplify the experimental procedure and avoid RNA contamination in the experimental process.
Provided is a reagent and method for high-throughput transcriptome in drug discovery and repositioning, which provides a fast and convenient method for drug screening. One step RT-PCR can not only simplify the experimental procedure but also avoid RNA contamination in the experimental process. Furthermore, the reagent and consumable used in the method is cheap and easy to obtain, therefore it can be carried out in ordinary laboratories. Taken together, this method can make drug screening easier and cheaper. Besides, one step RT-PCR method can be applied to high-throughput transcriptome sequencing, which facilitate the wide application of high-throughput transcriptome sequencing.
BEIJING CHUNLIZHENGDA MEDICAL INSTRUMENTS CO., LTD (China)
Inventor
Peng, Jiang
Wang, Zhenguo
Meng, Haoye
Lu, Qiang
Pan, Chao
Wang, Aiyuan
Zhou, Hao
Xu, Wenjing
Liu, Wei
Zhang, Xingyan
Shi, Chunbao
Cheng, Xi
Abstract
A fracture repair device capable of achieving transition from mechanical osteosynthesis (AO) to biological osteosynthesis (BO), comprising a bone repair instrument (1); an assisting assembly (2) is provided at the part of the bone repair instrument (1) close to the surface of a bone to be repaired, and the assisting assembly (2) is made of a degradable metal material or a composite material thereof or a degradable polymer material. The repair device has the advantage of strong mechanical osteosynthesis of AO, and can effectively overcome the defects such as bone nonunion, osteoporosis of a fixed segment, and re-fracture after de-fixation which frequently occur under the strong mechanical osteosynthesis of AO, achieving transition from mechanical osteosynthesis (AO) to biological osteosynthesis (BO) in a bone osteosynthesis or repair process.
The invention discloses a method for constructing functional exosomes capable of efficiently loading specific miRNA. In order to enable the exosome to carry miRNA with specific regulation function more efficiently so as to play a role in targeted regulation more accurately and efficiently, MS2 phage capsid protein is utilized to edit and construct a capture element of a specific miRNA molecule, and placenta mesenchymal stem cells are reprogrammed to enable the secreted exosome to efficiently load a target miRNA molecule, so that the target miRNA molecule is delivered to tissue cells to play a role in effective regulation, and therefore a new strategy is provided for realizing specific precise treatment in the future.
An intelligent monitoring system for pelvic fracture reduction, comprising a sample fracture model database, a patient pelvic fracture data acquisition unit, a reduction situation monitoring unit and a mixed reality data fusion processing unit, the sample fracture model database stores a plurality of sample fracture models, the patient pelvic fracture data acquisition unit uses magnetic navigation and positioning technology to collect patient pelvic location information data in real-time and upload it to the mixed reality data fusion processing unit, the mixed reality data fusion processing unit automatically invokes the sample fracture model in the sample fracture model database corresponding to patient pelvic fracture condition and matches the patient pelvic location information data with the sample fracture model using mixed reality technology to form an intelligent fracture model for the patient's pelvic fracture state, the reduction situation monitoring unit loads and displays images of the intelligent fracture model in different positions in real-time and monitors the reduction situation of different positions of the patient's pelvis in real-time. The system enhances treatment effect and reduces personnel radiation.
A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
A61B 34/20 - Surgical navigation systemsDevices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61B 34/00 - Computer-aided surgeryManipulators or robots specially adapted for use in surgery
22.
Medical application of pyrimidine sulfonamides derivatives
SHIJIAZHUANG SAGACITY NEW DRUG DEVELOPMENT COMPANY, LTD. (China)
Inventor
He, Kunlun
Gao, Xiaojian
Liu, Chunlei
Zhang, Zeyu
Li, Xin
Li, Chen
Luo, Yunfu
Lei, Maoyi
Li, Junmiao
Wang, Yiwei
Abstract
The present disclosure provides application of a compound in conformity with a general formula I and an isomer or pharmaceutically acceptable salt thereof to preparation of a medicinal composition for treating or preventing a high altitude disease. The high altitude disease is selected from an acute high altitude disease and a chronic high altitude disease generated in a high altitude environment with an altitude of 2,000 m or above.
Disclosed is a deep-learning-based method for predicting morphological change of a liver tumor after ablation. The method comprises: obtaining medical images of the liver tumor of the patient before and after ablation; pre-processing the medical images of before and after ablation; obtaining an image of the preoperative liver area and an image of the preoperative liver tumor area; obtaining an image of the postoperative liver area, an image of the postoperative ablation area, a ghost image of postoperative liver tumor; using CPD point set registration algorithm to obtain a transformation matrix, and obtain a registration result map according to the transformation matrix; training the network by means of a stochastic gradient descent method to obtain a liver tumor prediction model; using the liver tumor prediction model to predict morphological changes of the liver tumor in the patient after ablation. The present invention can predict the morphological changes of the liver tumor of the patient after ablation on the basis of CT/MRI images of the patient, which provides a basis for quantitatively assessing whether the ablation area completely covers the tumor, is beneficial for doctors to accurately evaluate the postoperative curative effect, and lays a foundation for the follow-up treatment plan for the patient.
A triad trocar device for deep tissue puncture, comprising: a thick puncture needle (10), a puncture cannula (20), and a fine puncture needle (30). In a puncture process, when shallow tissue is punctured, tips of the thick puncture needle (10), the puncture cannula (20), and the fine puncture needle (30) are aligned; when deep tissue is punctured, the puncture cannula (20) and the fine puncture needle (30) extend out of a first end of the thick puncture needle (10) and pierce into the deep tissue together, then the fine puncture needle (30) is withdrawn, and a channel is established between the deep tissue and the exterior of the body of a subject by means of the puncture cannula (20). By means of the puncturing device and method, important tissue organ damage can be reduced when the deep tissue is punctured, the sensitivity of the deep tissue during puncturing is increased, and the success rate of puncturing is improved, so that clinical prognosis is improved, and the device and method can be applied to clinical practice such as pericardial effusion puncture drainage and subclavian vein puncture catheterization, and have a high clinical application value.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
25.
TRIPLE MICRO-CATHETER DEVICE AND METHOD FOR TRANSTHORACIC AND EPICARDIAL INTRAMYOCARDIAL INJECTION UNDER ULTRASOUND GUIDANCE
A triple micro-catheter device, for transthoracic and epicardial intramyocardial injection under ultrasound guidance. The triple micro-catheter device comprises: a thick puncture needle (10), a micro-catheter (20), and a thin needle core (30). In a puncture process, the thin needle core (30) is inserted into the micro-catheter (20), and air tightness is formed between the thin needle core (30) and the micro-catheter (20); when a medicine is injected, the thin needle core (30) is withdrawn from the micro-catheter (20), and a second end of the micro-catheter (20) is connected to a medicine injection device. According to the device and the method thereof, two to three holes only need to be punctured in the chest wall of an experimental animal or a subject each time, the medicine can be injected into the myocardium via the thoracic epicardium by means of the micro-catheter (20) under the ultrasonic guidance, and the influence of heart beat on puncture needle positioning can be overcome; accurate administration is achieved, secondary myocardial injury is avoided, and the advantages of being high in local administration concentration, accurate and controllable in injection position, small in trauma, few in complications, capable of achieving administration for many times at different time points and the like are achieved. A convenient, safe and efficient intramyocardial administration mode is provided, and a high clinical translational value is achieved.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
26.
TRIPLE-PUNCTURE NEEDLE DEVICE AND METHOD FOR TRANSTHORACIC AND EPICARDIAL INTRAMYOCARDIAL INJECTION UNDER ULTRASOUND GUIDANCE
A triple-puncture needle device for transthoracic and epicardial intramyocardial injection under ultrasound guidance, comprising: a thick puncture needle, a fine puncture needle, a fine puncture needle core (30) and an extension hose (40), wherein the fine puncture needle is inserted into the thick puncture needle, and the fine puncture needle core (30) is inserted into the fine puncture needle. During injection, the fine puncture needle core (30) is withdrawn from the fine puncture needle; and an end base (41) of the extension hose (40) is combined with a base (21) of the fine puncture needle, so that the fine puncture needle communicates with the extension hose (40). By means of the present device, only two to three holes need to be punctured in the chest wall of a subject every time to inject drugs into the myocardium through the transthoracic epicardium by means of using the puncture needles under ultrasound guidance, and the device has the advantages of a high local drug delivery concentration, accurate and controllable injection positions, small wounds, few complications, and the ability to deliver drugs many times at different times. Meanwhile, the risk of the puncture needles directly injuring myocardial tissue and injuring epicardial blood vessels are reduced to the greatest extent, the problem of continuous heart palpitations is solved to a certain extent, accurate drug delivery is achieved, and myocardial secondary injury is prevented.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
27.
TISSUE-ENGINEERING BONE SCAFFOLD AND PREPARATION METHOD THEREFOR
A tissue-engineering bone scaffold and a preparation method therefor. The preparation method comprises the following steps: a cleaning step (S100): cleaning a tissue-engineering bone material by using a supercritical fluid, so as to remove soft tissues in the bone material to obtain an initial bone matrix; a sterilization step (S200): sterilizing the initial bone matrix by using the supercritical fluid to obtain a bone matrix; and a compounding step (S300): compounding cytokines inside holes of the bone matrix by means of the supercritical fluid to obtain a bone scaffold.
Disclosed are a growth factor sustained release microsphere, a tissue engineering cartilage composite stent and a manufacture method therefor. The growth factor sustained release microsphere comprises a polylactic acid-glycolic acid copolymer host material and a recombinant human transforming growth factor β3 encapsulated in the host material, wherein the encapsulation amount of the recombinant human transforming growth factor β3 in the microsphere is 5ng/mg～200ng/mg; the sustained release period of the microsphere is 28 days or more.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
A pelvic fracture reduction intelligent monitoring system, comprising a sample fracture model database, a patient pelvic fracture data acquisition unit, a reset situation monitoring unit, and a mixed reality data fusion processing unit. The sample fracture model database stores a plurality of sample fracture models; the patient pelvic fracture data acquisition unit utilizes a magnetic navigation and positioning technology to collect patient pelvic position information data and upload the data to the mixed reality data fusion processing unit; the mixed reality data fusion processing unit automatically calls a sample fracture model in the sample fracture model database corresponding to the patient pelvic fracture condition and utilizes a mixed reality technology to match the patient pelvic position information data with the sample fracture model to form an intelligent fracture model for the patient pelvic fracture state; and the reset situation monitoring unit loads and displays images of the intelligent fracture model in different positions in real time and monitors a reset situation of the patient pelvis at different positions in real time. The system enhances the treatment effect and reduces personnel radiation.
A61B 17/56 - Surgical instruments or methods for treatment of bones or jointsDevices specially adapted therefor
A61B 17/58 - Surgical instruments or methods for treatment of bones or jointsDevices specially adapted therefor for osteosynthesis, e.g. bone plates, screws or setting implements
SHIJIAZHUANG SAGACITY NEW DRUG DEVELOPMENT COMPANY, LTD. (China)
Inventor
He, Kunlun
Zhang, Zeyu
Gao, Xiaojian
Liu, Chunlei
Li, Xin
Li, Chen
Qian, Wenyuan
Yang, Chundao
Xu, Guanghai
Wang, Yiwei
Abstract
Disclosed are the use of a compound as shown in general formula I, and an isomer, or pharmaceutically acceptable salt thereof in the preparation of a pharmaceutical composition for treating and/or preventing altitude sickness. The altitude sickness is selected from acute altitude sickness or chronic altitude sickness caused by a high altitude environment of at least 2,000 m above sea level.
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61P 43/00 - Drugs for specific purposes, not provided for in groups
31.
MEDICAL APPLICATION OF PYRIMIDINE SULFONAMIDES DERIVATIVES
SHIJIAZHUANG SAGACITY NEW DRUG DEVELOPMENT COMPANY, LTD. (China)
Inventor
He, Kunlun
Gao, Xiaojian
Liu, Chunlei
Zhang, Zeyu
Li, Xin
Li, Chen
Luo, Yunfu
Lei, Maoyi
Li, Junmiao
Wang, Yiwei
Abstract
The invention provides a compound conforming to general formula (I) and the application of isomers or pharmacologically acceptable salts thereof in the preparation of a pharmaceutical composition for treating or preventing high altitude sickness. The altitude sickness is selected from acute and chronic altitude sicknesses occurred in an altitude environment with an altitude of 2,000m or above.
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
A61P 39/00 - General protective or antinoxious agents
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 9/00 - Drugs for disorders of the cardiovascular system
A tissue-engineering meniscus composite scaffold (100) and a preparation method therefor. The meniscus composite scaffold (100) comprises: a scaffold (110), wherein the scaffold (110) is C-shaped and consistent with the initial shape of meniscus to be regenerated and repaired, the scaffold (110) comprises a plurality of first degradable polymer fibers (111) extending in the circumferential direction of the scaffold (110) and a plurality of second degradable polymer fibers (112) extending in the radial direction of the scaffold (110), and the first degradable polymer fibers (111) and the second degradable polymer fibers (112) arranged crosswise in multiple layers to form a frame structure body having a plurality of first pores; and a matrix material (120) compounded inside the plurality of first pores of the scaffold (110) to form meniscus composite scaffold (100) having a plurality of second pores. The meniscus composite scaffold (100) has excellent mechanical properties and biocompatibility, and can provide an excellent microenvironment required for cell growth, thereby enabling newborn meniscus to have excellent shape, structure, mechanical properties, and physiological functions.
Provided is a use of a PD-1 antibody combined with an epigenetic regulator in the preparation of a drug for treating tumors. In particular, provided is a use of the PD-1 antibody combined with the epigenetic regulator in the preparation of a drug for treating tumors and/or enhancing T-cell activity.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
A portable medical electronic endoscopy system comprises an equipment container, a powering module (31), an endoscopic body, a light source device (4), a key circuit board (14), an image processing board (21) and a display module (11). The light source is in the equipment container. An upper layer (1) of the equipment container comprises a securing frame, in which the display module (11) is placed. The securing frame is detachably connected to the upper layer (1) of the equipment container, and comprises a connecting portion. When the support frame is placed at the upper layer (1) of the equipment container, the connecting port enables the display module (11) to be exactly electrically connected to the image processing board (21) and the powering module (31). The powering module (31), the light source device (4) and the display module (11) are entirely embedded in the portable medical endoscopy system, providing a compact structure that can be easily powered up, and making the system more readily portable. Further, the display module (11) can be more easily removed, mounted and selected, and can be conveniently connected to various components of the system.
A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
35.
Acrylamide compounds and use thereof for inhibiting apoptosis
The present invention relates to a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate of the compound, and to a composition comprising the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents. The present invention also relates to use of the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof for combating apoptosis, preventing or treating a disease or disorder associated with apoptosis; and especially use for protecting cardiomyocyte, and for preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
C07C 335/12 - Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing six-membered aromatic rings
C07D 295/21 - Radicals derived from sulfur analogues of carbonic acid
C07D 333/24 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 295/194 - Radicals derived from thio- or thiono carboxylic acids
A61K 31/4453 - Non-condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
The present invention relates to an acrylamide compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof, to a composition comprising the compound or an isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluent, and to a use of the compound or the composition for prophylaxis and/or treatment of a disease or disorder associated with cardiomyocyte apoptosis.
Provided are polyamide-amine (PAMAM) dendrimer or derivative thereof-Math1 gene nano particles, a preparation method therefor and a use thereof in treatment of hearing loss. The gene nano particles are prepared by subjecting PAMAM dendrimer or a derivative thereof, for example, PAMAM or a PAMAM-cyclodextrin complex activated through thermal treatment, and a Math1 gene containing plasmid to complex coacervation, and the gene nano particles are useful in treatment of sensorineural hearing loss caused by hair cell loss.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
The present invention discloses compounds of formula (I), isomers, pharmaceutical salts or solvates thereof. The present invention also discloses a composition comprising the compounds of formula (I), isomers, pharmaceutical salts or solvates thereof, and pharmaceutically acceptable carriers, excipients or diluents. The present invention also discloses the use of the compounds of formula (I), isomers, pharmaceutical salts or solvates thereof against apoptosis and for preventing and treating diseases or symptoms related to apoptosis, especially for protecting myocardium cells, preventing or treating diseases or symptoms related to myocardial apoptosis.
C07D 333/04 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulfur atom
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 295/21 - Radicals derived from sulfur analogues of carbonic acid
C07C 335/12 - Derivatives of thiourea having nitrogen atoms of thiourea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton the carbon skeleton containing six-membered aromatic rings
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/17 - Amides, e.g. hydroxamic acids having the group N—C(O)—N or N—C(S)—N, e.g. urea, thiourea, carmustine
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 43/00 - Drugs for specific purposes, not provided for in groups
39.
(2E)-3-PHENYL-N-[2,2,2-TRIFLUORO-1-[[(8-QUINOLINEAMINO)THIOMETHYL]AMINO]ETHYL]-2-ACRYLAMIDE AND PHARMACEUTICAL USES THEREOF
Acrylamide compounds of formula (I), or their isomers, pharmaceutically acceptable salts and solvates. Compositions containing said compounds or their isomers, pharmaceutically acceptable salts and solvates, and their pharmaceutically acceptable carriers, excipients or diluents. Uses of said compounds or said compositions for prevention and/or treatment of diseases or disorders related to myocardial cells apoptosis.
The present invention discloses compounds of formula (I), isomers, pharmaceutical salts or solvates thereof. The present invention also discloses a composition comprising the compounds of formula (I), isomers, pharmaceutical salts or solvates thereof, and pharmaceutically acceptable carriers, excipients or diluents. The present invention also discloses the use of the compounds of formula (I), isomers, pharmaceutical salts or solvates thereof against apoptosis and for preventing and treating diseases or symptoms related to apoptosis, especially for protecting myocardium cells, preventing or treating diseases or symptoms related to myocardial apoptosis.
C07C 275/24 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
C07C 275/26 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
C07C 275/28 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
C07D 215/40 - Nitrogen atoms attached in position 8
C07D 333/04 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulfur atom
patents
